Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Not yet recruiting · NCT07868926 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07868926 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 37 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||